ClinicalTrials.gg

Program

WS016

A development code. Also written as “WS016 Single Dose(6g)”, “WS016 Single Dose(12g)” and “WS016 Single Dose(24g)”.

Its studies are mostly in Hyperkalemia, led by Waterstone Pharmaceutical (Wuhan).

Furthest: phase 3, since Nov 18, 20254 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Waterstone Pharmaceutical (Wuhan)43 open or runningphase 3since Nov 18, 2025Feb 3, 2024Nov 2026phase 3 · NCT07251309

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2024First study: phase 2 study in HyperkalemiaFirst studyNCT06277128 · 140 planned · China
  2. Feb 19, 2024Phase 1 study in HyperkalemiaNCT06281470 · 66 enrolled · China
  3. Nov 18, 2025Phase 3 study in HyperkalemiaPhase 3 reachedNCT07251309 · 420 planned · China
  4. Oct 13, 2026Phase 3 study in HyperkalemiaNCT07881965 · 300 planned · China

Ahead

  1. Nov 2026Primary completion: phase 3 study in HyperkalemiaNCT07251309
  2. Feb 20, 2029Primary completion: phase 3 study in HyperkalemiaNCT07881965

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07881965Hyperkalemia · China3RecruitingFeb 20, 2029300
NCT07251309Hyperkalemia · China3RecruitingNov 2026420
NCT06281470Hyperkalemia · China1CompletedJun 15, 202366
NCT06277128Hyperkalemia · China2RecruitingApr 18, 2024140

How it is read

Names in the registry

  • “WS016”, 4 entries
  • “WS016 Single Dose(6g)”, 1 entry
  • “WS016 Single Dose(12g)”, 1 entry
  • “WS016 Single Dose(24g)”, 1 entry
  • “WS016 Single Dose(36g)”, 1 entry

Codes read as this program: WS016.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.